Suppr超能文献

用于治疗重症疟疾的青蒿素衍生物。

Artemisinin derivatives for treating severe malaria.

作者信息

McIntosh H M, Olliaro P

机构信息

Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK, L3 5QA.

出版信息

Cochrane Database Syst Rev. 2000;1998(2):CD000527. doi: 10.1002/14651858.CD000527.

Abstract

BACKGROUND

Artemisinin derivatives may have advantages over quinoline drugs for treating severe malaria since they are fast acting and effective against quinine resistant malaria parasites.

OBJECTIVES

The objective of this review was to assess the effects of artemisinin drugs for severe and complicated falciparum malaria in adults and children.

SEARCH STRATEGY

We searched the Cochrane Infectious Diseases Group trials register, Cochrane Controlled Trials Register, Medline, Embase, Science Citation Index, Lilacs, African Index Medicus, conference abstracts and reference lists of articles. We contacted organisations, researchers in the field and drug companies.

SELECTION CRITERIA

Randomised and pseudo-randomised trials comparing artemisinin drugs (rectal, intramuscular or intravenous) with standard treatment, or comparisons between artemisinin derivatives in adults or children with severe or complicated falciparum malaria.

DATA COLLECTION AND ANALYSIS

Eligibility, trial quality assessment and data extraction were done independently by two reviewers. Study authors were contacted for additional information.

MAIN RESULTS

Twenty three trials are included, allocation concealment was adequate in nine. Sixteen trials compared artemisinin drugs with quinine in 2653 patients. Artemisinin drugs were associated with better survival (mortality odds ratio 0.61, 95% confidence interval 0.46 to 0.82, random effects model). In trials where concealment of allocation was adequate (2261 patients), this was barely statistically significant (odds ratio 0.72, 95% CI 0.54 to 0.96, random effects model). In 1939 patients with cerebral malaria, mortality was also lower with artemisinin drugs overall (odds ratio 0.63, 95% CI 0.44 to 0.88, random effects model). The difference was not significant however when only trials reporting adequate concealment of allocation were analysed (odds ratio 0.78, 95% CI 0.55 to 1.10, random effects model) based on 1607 patients. No difference in neurological sequelae was shown. Compared with quinine, artemisinin drugs showed faster parasite clearance from the blood and similar adverse effects.

REVIEWER'S CONCLUSIONS: The evidence suggests that artemisinin drugs are no worse than quinine in preventing death in severe or complicated malaria. No artemisinin derivative appears to be better than the others.

摘要

背景

青蒿素衍生物在治疗重症疟疾方面可能比喹啉类药物更具优势,因为它们起效迅速,且对耐奎宁的疟原虫有效。

目的

本综述的目的是评估青蒿素类药物对成人和儿童重症及复杂恶性疟的疗效。

检索策略

我们检索了Cochrane传染病组试验注册库、Cochrane对照试验注册库、Medline、Embase、科学引文索引、Lilacs、非洲医学索引、会议摘要以及文章的参考文献列表。我们还联系了相关组织、该领域的研究人员和制药公司。

入选标准

比较青蒿素类药物(直肠给药、肌肉注射或静脉注射)与标准治疗的随机和半随机试验,或成人或儿童重症或复杂恶性疟中青蒿素衍生物之间的比较。

数据收集与分析

两名评审员独立进行资格审查、试验质量评估和数据提取。与研究作者联系以获取更多信息。

主要结果

纳入23项试验,其中9项分配隐藏充分。16项试验在2653例患者中比较了青蒿素类药物与奎宁。青蒿素类药物与更好的生存率相关(死亡比值比0.61,95%置信区间0.46至0.82,随机效应模型)。在分配隐藏充分的试验中(2261例患者),这一差异在统计学上勉强显著(比值比0.72,95%置信区间0.54至0.96,随机效应模型)。在1939例脑型疟患者中,总体上青蒿素类药物的死亡率也较低(比值比0.63,95%置信区间0.44至0.88,随机效应模型)。然而,在仅分析报告分配隐藏充分的试验时(基于1607例患者),差异不显著(比值比0.78,95%置信区间0.55至1.10,随机效应模型)。未显示神经后遗症方面的差异。与奎宁相比,青蒿素类药物显示出更快的血液寄生虫清除率和相似的不良反应。

综述作者结论

证据表明,在预防重症或复杂疟疾死亡方面,青蒿素类药物并不比奎宁差。没有一种青蒿素衍生物似乎比其他的更好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验